Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

NCT07218354 on ClinicalTrials.gov · last registry update 2026-09-21

Recruiting now, toward 622 participants. Due to report 31 March 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Two-level reduction in the World Health Organization (WHO) risk drinking level assessed in the last 28 days of intervention. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: VA Office of Research and Development
Sponsor type: Fed
Enrollment: 622
Started: 2026-07-28
Primary completion: 2029-03-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Two-level reduction in the World Health Organization (WHO) risk drinking level assessed in the last 28 days of intervention

Conditions studied

Alcohol Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.